Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells

Area of Science:

• Immunology
• Cell Biology
• Clinical Research

Background:

• Clinical application of dendritic cells (DCs) for immune tolerance is limited by the absence of standardized methods for generating human regulatory DCs.
• A critical barrier is the lack of reliable markers to identify these regulatory DCs for clinical studies.

Purpose of the Study:

• To identify simple, reliable markers for identifying human regulatory DCs generated for clinical applications.
• To establish quality control measures for regulatory DCs in future clinical studies.

Main Methods:

• Human DCs were generated from peripheral blood monocytes using 1alpha,25-dihydroxyvitamin D(3) (VD3).
• Phenotypic and functional characteristics of VD3-treated DCs were compared to untreated DCs.
• Levels of interleukin-23 secretion and expression of miR-155 and miR-378 were analyzed.

Main Results:

• VD3-treated DCs exhibited an immature DC phenotype with high CD14 and low CD1a.
• These DCs demonstrated inefficient T cell stimulation and induced T cell hyporesponsiveness with regulatory potential.
• VD3-treated DCs showed significantly lower interleukin-23 secretion and miR-155 expression, and higher miR-378 expression compared to untreated DCs upon maturation stimuli.

Conclusions:

• Low interleukin-23 secretion, low miR-155, and high miR-378 expression are robust markers for identifying VD3-treated regulatory DCs.
• These markers facilitate quality control for VD3-treated regulatory DCs in clinical settings.
• The identified markers support the advancement of DC-based immunotherapies.